A New Jersey pharmaceutical company has voluntarily recalled over 11,000 bottles of blood pressure medication after discovering cross-contamination with an unrelated cholesterol drug, raising fresh concerns about quality control in America’s drug manufacturing system.
Story Snapshot
- Glenmark Pharmaceuticals recalled 11,100+ bottles of Ziac blood pressure medication due to cholesterol drug contamination
- FDA classified this as a Class III recall, indicating a low risk of adverse health effects
- Contaminated bottles include multiple dosages with expiration dates from November 2025 through May 2026
- Incident highlights ongoing pharmaceutical quality control issues affecting American patients
Pharmaceutical Company Issues Voluntary Recall
Glenmark Pharmaceuticals Inc. of Elmwood Park, New Jersey, initiated a voluntary recall of bisoprolol fumarate and hydrochlorothiazide tablets marketed under the brand name Ziac.
The FDA announced that testing of reserve samples revealed the presence of ezetimibe. This cholesterol medication should not appear in blood pressure treatments. This cross-contamination affects both 2.5-milligram and 6.25-milligram doses across multiple bottle sizes.
High-blood pressure medication voluntarily recalled: FDA https://t.co/24m7XbqJA3 pic.twitter.com/m0hNxFrXYS
— WATE 6 On Your Side (@6News) December 6, 2025
Scope and Classification of Drug Recall
The recall encompasses 30-count bottles (NDC 68462-878-30), 100-count bottles (NDC 68462-878-01), and 500-count bottles (NDC 68462-878-05). Affected lot numbers carry expiration dates spanning from November 2025 through May 2026.
The FDA designated this as a Class III recall, indicating that use or exposure to the contaminated product is “not likely to cause adverse health consequences” according to federal health officials.
Quality Control Concerns in Drug Manufacturing
This incident underscores persistent quality control challenges within pharmaceutical manufacturing that directly impact American families relying on prescription medications. Cross-contamination between different drug types represents a serious breach of manufacturing protocols that could potentially create unpredictable health effects.
While the FDA rates this particular contamination as low-risk, the broader pattern of drug recalls continues to erode confidence in pharmaceutical oversight and manufacturing standards.
Patient Safety and Regulatory Response
Americans taking the affected Ziac medication should immediately check their bottle labels against the recalled NDC numbers and consult their healthcare providers if they possess contaminated products.
The voluntary nature of this recall demonstrates industry self-policing, yet raises questions about detection timelines and prevention measures. Patients deserve assurance that their prescription medications contain only intended active ingredients, particularly when managing serious conditions like high blood pressure that affect millions of Americans daily.
